Table 1.
Patient characteristics
| Patients | Overall (118) | B-ALL (53) | LBCL (65) |
|---|---|---|---|
| Age (y), median (range) | 58 (20-86) | 44 (22-74) | 64 (20-86) |
| Sex (male), n (%) | 84 (71) | 39 (74) | 45 (69) |
| ECOG preinfusion, n (%) | |||
| 0-1 | 109 (93) | 53 (100) | 56 (86) |
| 2-4 | 7 (6) | 0 | 7 (11) |
| Not available | 2 (1) | 0 | 2 (3) |
| Disease burden preinfusion, n (%) | |||
| High | 78 (66) | 33 (62)* | 45 (69)† |
| Low | 37 (31) | 20 (38)‡ | 17 (26)§ |
| N/A¶ | 3 (3) | 0 | 3 (5) |
| IPI preinfusion, n (%) | |||
| Low/intermediate low (0-2) | — | — | 39 (60) |
| High/intermediate high (3-5) | — | — | 22 (35) |
| Not available | — | — | 3 (5) |
| Fever before/during lymphodepletion, n (%) | 23 (19) | 10 (19) | 13 (20) |
| Lymphodepleting chemotherapy, n (%) | |||
| Fludarabine/cyclophosphamide | 72 (61) | 10 (19) | 62 (95) |
| High-dose cyclophosphamide | 43 (36) | 43 (81) | — |
| Bendamustine | 3 (3) | — | 3 (5) |
| CAR T-cell product, n (%) | |||
| CD1928z | 53 (45) | 53 (100) | 0 (0) |
| Axicabtagene ciloleucel | 44 (37) | 0 (0) | 44 (68) |
| Tisagenlecleucel | 21 (18) | 0 (0) | 21 (32) |
CR, complete response; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; N/A, not applicable.
*
BM blasts > 5%.
†
Stage 3 to 4 and/or bulky >6 cm.
‡
BM blasts < 5%.
§
Stage 1 or 2.
¶
Patients in CR at infusion